Close Menu

stock price

Beckman Coulter's shares dropped around 7 percent after the firm disclosed that an ongoing issue surrounding its troponin test kits could lead to further restrictions on the test and may have a material impact on its results.

Leerink Swann dropped coverage of Helicos, citing both short-term and long-term challenges. It also called an acquisition of the firm unlikely.

Macquarie Securities increased its target share price and revenue estimates and upgraded Agilent's stock to "outperform" based on several catalysts.

Shares of Interleukin rose after the firm said that the results of a retrospective study suggest that individuals who base their diet on genotype could potentially benefit from the firm's weight management genetic test.

An analyst placed a $16 price target on Sequenom's shares, which closed at $6.92 yesterday.

Sequenom shares rose on the news of two product launches during the month, while Nanosphere's shares dropped following its Q4 financial report.

The firms would not confirm the offer, but two news agencies have claimed that sources have verified that the bid has been made.

The firm's shares eclipsed the $5 mark for the first time since last year's dismissal of its CEO and other executives following an investigation into the mishandling of test data on its Down Syndrome test.

Robert W. Baird upped its rating on Sigma-Aldrich's shares the day after the firm beat analysts' estimates for Q4 2009.

The investment bank maintained its 12-month price targets on the respective stocks. It said that Genomic Health was trading at an "attractive entry point."


Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.

Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.

Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.

In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.